PARIS & PHILADELPHIA–(BUSINESS WIRE)–Bioptimus, a French startup building the reference AI foundation model in biology, is excited to announce that its best-in-class H-optimus-0 foundation model is now integrated into Proscia’s Concentriq® Embeddings, enabling data scientists and researchers in pathology and life sciences to achieve breakthroughs in AI development at unprecedented speed and scale. This integration adds H-optimus-0 to the collection of foundation models that Concentriq Embeddi

LONDON–(BUSINESS WIRE)–QbTest Evaluated and Recommended by the National Institute for Health and Care Excellence Diagnostic Assessment Programme

Nuclidium announced that the first patient has been successfully imaged in a phase 1 clinical trial evaluating the company’s radiotracer candidate as a safe and accurate diagnostic and disease─staging imaging agent in prostate cancer patients. 61Cu─NuriPro (61Cu─NODAGA─PSMA I&T) is the diagnostic

Citeline was delighted to be able to recognize and celebrate excellence across the Japanese pharma, biotech and clinical research industries at the 3rd Citeline Japan Awards, held at the Palace Hotel

      

Annual report of the Pharmacovigilance Inspectors Working Group for 2023

BeiGene, Ltd., a global oncology company, announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency issued positive opinions recommending an extended authorization for Tevimbra (tislelizumab) in gastric or gastroesophageal junction (G/GEJ) adenocarcinoma and esophageal squamous cell carcinoma (ESCC).

RICHMOND, Calif.–(BUSINESS WIRE)–Oct. 22, 2024– Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the outcome of a recent successful interaction with the U.S. FDA, providing a clear regulatory pathway to…

**Title: ProQR Therapeutics Secures $87M in Funding Through Public Offering and Private Placement** ProQR Therapeutics, a leader in RNA-based therapies, has announced the successful pricing of its $75 million public offering alongside a $12 million private placement. This strategic funding aims to bolster the company’s financial position as it progresses its innovative pipeline, particularly in

Citeline was delighted to be able to recognize and celebrate excellence across the Japanese pharma, biotech and clinical research industries at the 3rd Citeline Japan Awards, held at the Palace Hotel

      

HAYWARD, Calif.–(BUSINESS WIRE)–Jan 21, 2013 – Impax Pharmaceuticals, a division of Impax Laboratories, Inc., announced today that the U.S. Food and Drug Administration (FDA) issued a complete response letter regarding the New Drug Application…